375 related articles for article (PubMed ID: 17902149)
1. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.
Boogaard R; de Jongste JC; Merkus PJ
Pediatr Pulmonol; 2007 Nov; 42(11):989-1001. PubMed ID: 17902149
[TBL] [Abstract][Full Text] [Related]
2. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
Tarrant BJ; Le Maitre C; Romero L; Steward R; Button BM; Thompson BR; Holland AE
Respirology; 2017 Aug; 22(6):1084-1092. PubMed ID: 28397992
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
[TBL] [Abstract][Full Text] [Related]
4. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
King M; Dasgupta B; Tomkiewicz RP; Brown NE
Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
[TBL] [Abstract][Full Text] [Related]
5. The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care?
Bilton D; Stanford G
Curr Opin Pulm Med; 2014 Nov; 20(6):601-6. PubMed ID: 25221855
[TBL] [Abstract][Full Text] [Related]
6. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.
Suri R; Metcalfe C; Lees B; Grieve R; Flather M; Normand C; Thompson S; Bush A; Wallis C
Lancet; 2001 Oct; 358(9290):1316-21. PubMed ID: 11684212
[TBL] [Abstract][Full Text] [Related]
7. The use of pulmonary clearance medications in the acutely ill patient.
Papacostas MF; Luckett P; Hupp S
Expert Rev Respir Med; 2017 Oct; 11(10):815-826. PubMed ID: 28780895
[TBL] [Abstract][Full Text] [Related]
8. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
Suri R; Metcalfe C; Wallis C; Bush A
Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
[TBL] [Abstract][Full Text] [Related]
9. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Paediatr Respir Rev; 2006; 7 Suppl 1():S215-9. PubMed ID: 16798570
[TBL] [Abstract][Full Text] [Related]
10. Mucoactive agents for adults with acute lung conditions: A systematic review.
Tarrant BJ; Maitre CL; Romero L; Steward R; Button BM; Thompson BR; Holland AE
Heart Lung; 2019; 48(2):141-147. PubMed ID: 30409442
[TBL] [Abstract][Full Text] [Related]
11. Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis.
Amirav I; Cohen-Cymberknoh M; Shoseyov D; Kerem E
Paediatr Respir Rev; 2009 Jun; 10(2):58-62. PubMed ID: 19410203
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic agents for mucus clearance in bronchiectasis.
Nair GB; Ilowite JS
Clin Chest Med; 2012 Jun; 33(2):363-70. PubMed ID: 22640851
[TBL] [Abstract][Full Text] [Related]
13. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
14. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
15. Aerosol Medications for Treatment of Mucus Clearance Disorders.
Rubin BK
Respir Care; 2015 Jun; 60(6):825-9; discussion 830-32. PubMed ID: 26070577
[TBL] [Abstract][Full Text] [Related]
16. The role of mucoactive agents in the mechanically ventilated patient: a review of the literature.
Icard BL; Rubio E
Expert Rev Respir Med; 2017 Oct; 11(10):807-814. PubMed ID: 28737047
[TBL] [Abstract][Full Text] [Related]
17. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis.
Robinson M; Regnis JA; Bailey DL; King M; Bautovich GJ; Bye PT
Am J Respir Crit Care Med; 1996 May; 153(5):1503-9. PubMed ID: 8630593
[TBL] [Abstract][Full Text] [Related]
18. Inhaled mucoactive drugs for treating non-cystic fibrosis bronchiectasis in children.
Snijders D; Calgaro S; Bertozzi I; Quartesan S; Kozuh I; Lunardi F; Barbato A
Int J Immunopathol Pharmacol; 2013; 26(2):529-34. PubMed ID: 23755770
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
Griese M; App EM; Duroux A; Burkert A; Schams A
Pulm Pharmacol Ther; 1997; 10(1):21-7. PubMed ID: 9344829
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the efficacy of mucoactive aerosol therapy.
Fuloria M; Rubin BK
Respir Care; 2000 Jul; 45(7):868-73. PubMed ID: 10926385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
